Milan, March 4, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products in the field of loco-regional radiotherapy to treat solid…
read moreMilan, January 15, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical stage company developing novel medical device products with a primary focus in the field of loco-…
read moreThe Board of Directors welcomes new Board Members Giovanni Cerutti and Luca Melindo who will support the company's future growth The Ordinary Shareholder’s Meeting of BetaGlue Technologies appointed the new…
read moreBetty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas
read moreAccording to the article featured in the international peer-reviewed journal, BAT-90 could be considered a safe and innovative therapeutic option for unresectable solid liver tumors BetaGlue Technology’s Antonino Amato and…
read moreThe raised capital will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90 , thus opening a new chapter in the fight against cancer BetaGlue Technologies…
read moreThe first clinical findings have shown that BAT-90 makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy…
read moreBetaGlue (www.betaglue.com), an innovative Italian company in the field of interventional oncology today announced the appointment of its new Board of Directors, composed by investors representatives, independent industry experts and…
read more
